Table 5 Statistics of whole-exome sequencing
From: Multi-omics data integration reveals novel drug targets in hepatocellular carcinoma
SAMPLE | Total number of reads | Mean Target Coverage | % target bases covered at least 10X | % target bases covered at least 20X | % target bases covered at least 50X | % target bases covered at least 100X |
|---|---|---|---|---|---|---|
357muscle | 55,062,491 | 35.5 | 88.9% | 66.7% | 19.6% | 3.3% |
368muscle | 68,408,757 | 43.6 | 92.1% | 75.1% | 28.2% | 5.8% |
373muscle | 125,208,792 | 69.7 | 96.1% | 88.5% | 54.2% | 18.3% |
358muscle | 249,603,786 | 128.7 | 98.0% | 95.4% | 80.1% | 49.2% |
358N1 | 52,236,649 | 33.8 | 88.1% | 64.8% | 18.1% | 3.0% |
357N5 | 59,870,967 | 37.5 | 90.0% | 69.5% | 22.3% | 4.1% |
368N8 | 69,492,339 | 43.2 | 91.9% | 75.0% | 28.6% | 6.1% |
373N4 | 92,890,008 | 55.4 | 94.0% | 82.4% | 42.4% | 12.2% |
368N2 | 126,289,004 | 63.6 | 95.8% | 87.2% | 50.1% | 15.5% |
357N1 | 140,082,301 | 77.6 | 96.2% | 89.4% | 59.0% | 23.8% |
358N3 | 144,107,456 | 78.4 | 96.5% | 90.2% | 61.2% | 25.2% |
373N3 | 141,719,445 | 84.8 | 96.7% | 91.0% | 64.2% | 28.4% |
357N4 | 172,106,294 | 91.2 | 97.2% | 92.4% | 67.3% | 31.1% |
368N4 | 207,370,862 | 110.2 | 97.9% | 94.8% | 76.5% | 42.3% |
358N2 | 209,306,186 | 113.7 | 97.8% | 94.5% | 76.3% | 43.0% |
373N1 | 235,568,319 | 123.9 | 97.9% | 95.0% | 79.0% | 47.9% |